Alaunos Therapeutics dismisses RSM, engages Cherry Bekaert as auditor

Alaunos Therapeutics, Inc.

Dismissed RSM US LLP as independent auditor on June 19, 2024; no disagreements reported.
Appointed Cherry Bekaert LLP as successor independent auditor effective June 19, 2024.
RSM's reports for FY 2023 and 2022 included going concern qualification.
Change approved by Audit Committee; no reportable events in prior periods.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.